Alkion BioInnovations, a biotechnology company, is developing an innovative plant-based bioproduction platform dedicated to active ingredients and saponin-based adjuvants for next-generation vaccines. By combining technological innovation, sustainability, and industrial sovereignty, Alkion provides a strategic response to major global health challenges. The company announces a €4.4 million financing round led by GO Capital and Critical Path Ventures. Alkion BioInnova,ons cult

Paris, July 3, 2025 – BrainEver, a biotechnology company focused on neurodegenerative diseases, today announced the successful completion of its €33 million Series B financing round. This funding will support the launch of the company’s first clinical trial in Europe for its lead therapeutic candidate targeting amyotrophic lateral sclerosis (ALS). The round was co-led by Critical Path Ventures and the European Innovation Council (EIC), with continued support from existing in

Funds will enable company to launch a clinical trial in patients with drugresistant depression and finalize development of its non-invasive technology. Sonomind’s personalized transcranial neuromodulation system enables noninvasive targeting of deep brain regions with unprecedented precision, addressing areas involved in wide range of psychiatric and neurological disorders. Paris, France, September 24, 2025 – Sonomind, a company developing a unique medical device for non-inva

Funds raised will help accelerate time to market in Europe for MultiSense and scale industrial operations. Plans include starting a health economics study to support MultiSense’s reimbursement application, alongside preparing registration procedures with US authorities, with an eye on US launch in 2028. Strasbourg, France, September 29, 2025 – RDS , a French medtech company, today announces a €14 million ($16.6M) Series A funding round. The SPI (Sociétés de Projets Industrie